Volume 36 Issue 6
Nov.  2020
Turn off MathJax
Article Contents
Article Navigation >  Journal of Nanjing University of traditional Chinese Medicine  > 2020  >  36(6): 907-914
MAQin-hai, CHENRui-han, YANGZi-feng. Study on the Potential Material Basis and Molecular Mechanism of Liushen Capsule on the Treatment of COVID-19 Through the Network Pharmacology and Molecular Docking[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(6): 907-914.
Citation: MAQin-hai, CHENRui-han, YANGZi-feng. Study on the Potential Material Basis and Molecular Mechanism of Liushen Capsule on the Treatment of COVID-19 Through the Network Pharmacology and Molecular Docking[J]. Journal of Nanjing University of traditional Chinese Medicine, 2020, 36(6): 907-914.
shu

Study on the Potential Material Basis and Molecular Mechanism of Liushen Capsule on the Treatment of COVID-19 Through the Network Pharmacology and Molecular Docking

  • 1.

    State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 511436, China

  • 2.

    Faculty of Chinese Medicine, Macau University of Science and Technology, Macau, 519020, China

  • 3.

    KingMed Virology Diagnostic & Translational Center, Guangzhou, 510725, China

  • Publish Date: 2020-11-10
    Abstract
  • OBJECTIVE To explore the potential material basis and molecular mechanism of Liushen Capsule on inhibiting COVID-19 through network pharmacology and molecular docking technology. METHODS The effective monomers and targets of realgar， calculus bovis artifacts， borneolum， bufonis venenum and moschus in Liushen Capsule were searched with the help of the network pharmacology databases. Based on UniProt database and Cytoscape 3.6.1 software， the gene corresponding to the target was queried， and the network of traditional Chinese medicine-effective ingredients-effective target was constructed. GO， KEGG， Reactome enrichment analysis were carried out by Metascape platform to predict the mechanism of action. Molecular docking of the top 15 monomers was carried out in the medicinal material-compound-target network with SARS-CoV-2 3CL hydrolase， angiotensin-converting enzyme Ⅱ (ACE2)， and SARS-CoV-2 RNA dependent RNA polymerase (RdRp). RESULTS The network of TCM-active ingredients-effective targets included 5 herbs， 136 compounds and 2 082 targets. The key targets were PTGS2、ESR1、PLA2G1B and PTGS1. The function enrichment analysis of GO was 495 (P<0.05)， of which there were 287 biological processes (BP)， and 96 related items of cell composition (CC)， and 112 molecular function (MF) items. There were 107 signal pathways (P<0.05) in the KEGG pathway enrichment screening， which mainly involved cancer pathway， neuroactive ligand receptor interaction， cell growth， metabolism， apoptosis related pathway， immunity and inflammation. There were 85 signal pathways (P<0.05) in the Reactome pathway enrichment screening， which were mainly involved in nervous system， G protein coupling， interleukin signal， receptor tyrosine kinase signal and gene transcription. The results of molecular docking showed that the affinity of ergotamine， ursolic acid， chenodeoxycholic acid and other core active compounds in Liushen Capsule with SARS-CoV-2 3CL and ACE2 was similar to that of clinically recommended chemicals. CONCLUSION The active compounds in Liushen Capsule， ergotamine， ursolic acid and chenodeoxycholic acid， may regulate multiple signal pathways by binding to ACE2 to act on targets such as PTGS2， ESR1， PLA2G1B and PTGS1， thereby inhibit SARS-CoV-2.

     

    • FullText(HTML)
  • loading
    • References(37)
  • [1]
    ZHU N， ZHANG DY， WANG WL， et al. A novel coronavirus from patients with pneumonia in China， 2019[J]. N Engl J Med， 2020， 382(8): 727-733.
    [2]
    MAHASE E. China coronavirus: WHO declares international emergency as death toll exceeds 200[J]. BMJ， 2020， 368: 408.
    [3]
    WANG WE， TANG JM， WEI FQ. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan， China[J]. J Med Virol， 2020， 92(4): 441-447.
    [4]
    国家卫生健康委员会国家中医药管理局. 新型冠状病毒肺炎诊疗方案(试行第七版)[J]. 江苏中医药， 2020，52(4):1-6.
    [5]
    李丽，杨华升，勾春燕，等. 46例新型冠状病毒肺炎中医临床特征分析[J]. 首都医科大学学报， 2020，41(2):155-160.
    [6]
    陈瑞，罗亚萍，徐勋华，等. 基于武汉地区52例新型冠状病毒肺炎的中医证治初探及典型病案分析[J]. 中医杂志，2020，62（9）：741-744.
    [7]
    郑国华，王桂红. 六神丸的临床应用和药理研究进展[J]. 湖北中医杂志， 1996，18(4):56.
    [8]
    韩树景， 裴改社. 六神丸的临床运用[J]. 中国民族民间医药杂志， 2000， 9(1): 57-58.
    [9]
    孙兆泉， 剪林宏， 肖梅英， 等. 六神含片抗流感病毒及细菌感染作用的实验研究[J]. 湖南中医药导报， 1997， 3(5): 23-24.
    [10]
    LI XJ， JIA MM， LI YS， et al. Involvement of substance p/neurokinin-1 receptor in the analgesic and anticancer activities of minimally toxic fraction from the traditional Chinese medicine Liu-Shen-Wan in vitro[J]. Biol Pharm Bull， 2014， 37(3): 431-438.
    [11]
    MA HY， KOU JP， ZHU DN， et al. Liu-Shen-Wan， a traditional Chinese medicine， improves survival in Sepsis induced by cecal ligation and puncture via reducing TNF-α levels， MDA content and enhancing macrophage phagocytosis[J]. Int Immunopharmacol， 2006， 6(8): 1355-1362.
    [12]
    MA HY， KOU JP， WANG JR， et al. Evaluation of the anti-inflammatory and analgesic activities of Liu-Shen-Wan and its individual fractions[J]. J Ethnopharmacol， 2007， 112(1): 108-114.
    [13]
    MA QH， HUANG WB， ZHAO J， et al. Liu Shen Wan inhibits influenza a virus and excessive virus-induced inflammatory response via suppression of TLR4/NF-κB signaling pathway in vitro and in vivo[J]. J Ethnopharmacol， 2020， 252: 112584.
    [14]
    上海市卫生健康委员会.上海市新型冠状病毒肺炎中医诊疗方案（试行第二版）[EB/OL].（2020-02-24）[2020-08-15]http://wsjkw.sh.gov.cn/zyygz2/20200224/a1f1aab9745e4490867cb 4aaf40eaad0.html.
    [15]
    XU QH， BAUER R， HENDRY BM， et al. The quest formodernisation of traditional Chinese medicine[J]. BMC Complement Altern Med， 2013， 13: 132.
    [16]
    HOPKINS AL. Network pharmacology[J]. Nat Biotechnol，2007，25(10): 1110-1111.
    [17]
    赵丽琴， 肖军海， 李松. 分子对接在基于结构药物设计中的应用[J]. 生物物理学报， 2002， 18(3): 263-270.
    [18]
    许海玉， 刘振明， 付岩， 等. 中药整合药理学计算平台的开发与应用[J]. 中国中药杂志， 2017， 42(18): 3633-3638.
    [19]
    XU M， SHI J， MIN Z， et al. A network pharmacology approach to uncover the molecular mechanisms of herbal formula Kang-bai-Ling for treatment of vitiligo[J]. Evid Based Complement Alternat Med， 2019， 2019: 3053458.
    [20]
    黄漠然， 赵文靖， 李晋生， 等. 牛黄及其代用品化学成分、分析方法和药理作用研究进展[J]. 药物分析杂志， 2018， 38(7): 1116-1123.
    [21]
    闫焕，赵文静，常惟智.牛黄的药理作用及临床应用研究进展[J]. 中医药信息， 2013， 30(2): 114-116.
    [22]
    陈瀛澜，郝艳艳，郭夫江，等.蟾酥化学成分及药理活性研究进展[J]. 中草药， 2017， 48(12): 2579-2588.
    [23]
    罗世兰，廖利，邹琼芳，等.冰片的研究进展[J].中国民族民间医药，2018，27(5): 73-76.
    [24]
    陈艳红， 冯玉林. 冰片的研究进展[J]. 中国社区医师(医学专业)， 2013， 15(6): 10-11.
    [25]
    蒋且英， 罗云， 谭婷， 等. 气质联用和化学计量学比较不同品种和产地麝香挥发性成分组成[J]. 中国实验方剂学杂志， 2018， 24(3): 49-55.
    [26]
    杨弘， 吴树华， 俞磊明. GC-MS联用对麝香中多组分定性分析的研究[J]. 中成药， 2013， 35(9): 1966-1968.
    [27]
    徐森楠， 庄莉， 翟园园， 等. 基于网络药理学研究二至丸防治骨质疏松症的物质基础与作用机制[J]. 中国药学杂志， 2018， 53(22): 1913-1920.
    [28]
    李建生， 李素云， 谢洋. 河南省新型冠状病毒肺炎中医辨证治疗思路与方法[J]. 中医学报， 2020， 35(3): 453-457.
    [29]
    郑文科， 张俊华， 杨丰文， 等. 中医药防治新型冠状病毒肺炎各地诊疗方案综合分析[J]. 中医杂志， 2020， 61(4): 277-280.
    [30]
    苗万， 刘亚平. 六神丸的药理研究[J]. 中国药物与临床， 2011， 11(8): 935-936.
    [31]
    MA QH， PAN WQ， LI RF， et al. Liu Shen capsule shows antiviral and anti-inflammatory abilities against novel coronavirus SARS-CoV-2 via suppression of NF-κB signaling pathway[J]. Pharmacol Res， 2020， 158: 104850.
    [32]
    WALLS AC， PARK YJ， TORTORICI MA， et al. Structure， function， and antigenicity of the SARS-CoV-2 spike glycoprotein[J]. Cell， 2020， 181(2): 281-292.
    [33]
    ZIEBUHR J. The coronavirus replicase[J].Curr Top Microbiol Immunol， 2005，287:57-94.
    [34]
    AHMAD J， IKRAM S， AHMAD F， et al. SARS-CoV-2 RNA Dependent RNA polymerase (RdRp)： A drug repurposing study[J]. Heliyon，2020， 6(7): e04502.
    [35]
    CHENG LT， YEH MM， LU CC. Phenobarbital-induced liver injury with nodal angiomatosis[J]. Hepatology， 2019， 70(1): 437-439.
    [36]
    LI H， CHEN LZ， LI SM， et al. Incorporation of privileged structures into 3-O-β-chacotriosyl ursolic acid can enhance inhibiting the entry of the H5N1 virus[J]. Bioorg Med Chem Lett， 2019， 29(18): 2675-2680.
    [37]
    LUO L， HAN WL， DU JY， et al. Chenodeoxycholic acid from bile inhibits influenza A virus replication via blocking nuclear export of viral ribonucleoprotein complexes[J]. Molecules， 2018， 23(12): E3315.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (448) PDF downloads(310) Cited by()
    Proportional views
    Related

    Copyright © Journal of Nanjing University of traditional Chinese Medicine

    Sponsored by：Nanjing University of traditional Chinese MedicineAddress：No.138 xianlin Avenue, Qixia District, Nanjing cityChina Pos：210023

    Tel：025-85811935Email：xb@njucm.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return